Abstract
The severe acute respiratory syndrome coronavirus 2, which is responsible for the COVID-19 pandemic, causes severe respiratory illness. The condition was initially discovered in December 2019 and spread all over to the world, causing 6724248 deaths by January 25th 2023 worldwide. Through the course of three years from 2019 to 2022, the virus has developed multiple variants from Alpha, Beta, Gamma, Delta and Omicrons. In response to a virus with such a rapidly mutating virus, the development of mRNA vaccines has been prioritized. The easiness of producing mRNA vaccine allowing less time can be spent on the development phase of a vaccine. Thus, mRNA vaccines can also be updated frequently to keep up the mutations in the virus. Three mRNA vaccines are described in this article (two of them are currently available and one is still developing) in terms of target protein, effectiveness, adverse effects and price and compare them to give recommendations for different cohorts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
